Literature DB >> 15567432

Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.

Seiichiro Mori1, Lina Wang, Takamasa Takeuchi, Tadahito Kanda.   

Abstract

We demonstrated the presence of two adeno-associated viruses (AAVs), designated AAV10 and AAV11, in cynomolgus monkeys by isolating and sequencing the entire viral coding regions from the monkey DNA. AAV10 and AAV11 capsid proteins shared 84% and 65%, respectively, of amino acids with AAV2. A phylogenetic analysis of AAV capsid proteins showed that AAV10 and AAV11 resembled most AAV8 and AAV4, respectively. To characterize the capsid protein, we pseudotyped an AAV2 vector with the monkey AAV capsid proteins and examined the resulting pseudotypes AAV2/10 and AAV2/11, in comparison with the AAV2 vector, for their host ranges in cell lines and tissue tropism in mice. AAV2/10 and AAV2/11 transduced primate cells less efficiently than AAV2. Whereas AAV2 transduced undifferentiated C2C12 mouse myoblasts more efficiently than differentiated ones, AAV2/10 and AAV2/11 transduced the undifferentiated myoblasts less efficiently than differentiated ones. Three weeks after injection to the muscle of the hind legs, AAV2/10 and AAV2 induced transgene expression similarly, but AAV2/11 did not transduce the skeletal muscle. Six weeks after systemic administration, transduced vector DNA was detected by PCR in the liver and spleen of mice inoculated with AAV2, in the liver, heart, muscle, lung, kidney, and uterus of mice with AAV2/10, and the muscle, kidney, spleen, lung, heart, and stomach of mice with AAV2/11. Mouse antisera against capsid protein VP2 of the three AAVs neutralized the respective vector particles in a type-specific manner. The results indicate that AAV10 and AAV11 capsid proteins, which are antigenically distinct from each other and AAV2, are likely to determine their host ranges and tissue tropism that are different from AAV2s, suggesting that cynomolgus AAVs could provide a broader choice of pseudotype AAV vectors for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567432     DOI: 10.1016/j.virol.2004.10.012

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  85 in total

Review 1.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

2.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6.

Authors:  Zhijian Wu; Edward Miller; Mavis Agbandje-McKenna; Richard Jude Samulski
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.

Authors:  Ziying Yan; Diana C M Lei-Butters; Xiaoming Liu; Yulong Zhang; Liang Zhang; Meihui Luo; Roman Zak; John F Engelhardt
Journal:  J Biol Chem       Date:  2006-08-09       Impact factor: 5.157

5.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 6.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 7.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

9.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.

Authors:  Piotr Hadaczek; John Forsayeth; Hanna Mirek; Keith Munson; John Bringas; Phil Pivirotto; Jodi L McBride; Beverly L Davidson; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

10.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.